Prof William Hope FRACP, FRCPA, PhD

Professor of Therapeutics and Infectious Diseases Molecular and Clinical Pharmacology

    Publications

    2019

    Amphotericin B Penetrates into the Central Nervous System Through Focal Disruption of the Blood Brain Barrier in Experimental Hematogenous Candida Meningoencephalitis. (Journal article)

    Petraitis, V., Petraitiene, R., Valdez, J. M., Pyrgos, V., Lizak, M. J., Klaunberg, B. A., . . . Walsh, T. J. (2019). Amphotericin B Penetrates into the Central Nervous System Through Focal Disruption of the Blood Brain Barrier in Experimental Hematogenous Candida Meningoencephalitis.. Antimicrobial agents and chemotherapy. doi:10.1128/aac.01626-19

    DOI: 10.1128/aac.01626-19

    Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis (Journal article)

    Kovanda, L. L., Giamberardino, C., McEntee, L., Toffaletti, D. L., Franke, K. S., Bartuska, A., . . . Perfect, J. R. (2019). Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(9). doi:10.1128/AAC.00546-19

    DOI: 10.1128/AAC.00546-19

    Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multi-Drug Resistant Gram-Negative Infections. (Journal article)

    McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Dane, A., Jain, A., . . . Hope, W. (2019). Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(8). doi:10.1128/AAC.00603-19

    DOI: 10.1128/aac.00603-19

    Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model (Journal article)

    Avedissian, S. N., Pais, G. M., O'Donnell, J. N., Lodise, T. P., Liu, J., Prozialeck, W. C., . . . Scheetz, M. H. (2019). Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(8), 2326-2334. doi:10.1093/jac/dkz167

    DOI: 10.1093/jac/dkz167

    POPULATION PHARMACOKINETICS OF ANIDULAFUNGIN IN CRITICALLY ILL PATIENTS. (Journal article)

    Luque, S., Hope, W., Campillo, N., Munoz-Bermudez, R., Sorli, L., Barcelo-Vidal, J., . . . Grau, S. (2019). Population Pharmacokinetics of Anidulafungin in Critically III Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(7). doi:10.1128/AAC.00378-19

    DOI: 10.1128/aac.00378-19

    Population Pharmacokinetic Modeling of VL-2397, A Novel Systemic Antifungal Agent: Analysis of a Single and Multiple Ascending Dose Study in Healthy Subjects. (Journal article)

    Kovanda, L. L., Sullivan, S. M., Smith, L. R., Desai, A. V., Bonate, P. L., & Hope, W. W. (2019). Population Pharmacokinetic Modeling of VL-2397, A Novel Systemic Antifungal Agent: Analysis of a Single and Multiple Ascending Dose Study in Healthy Subjects.. Antimicrobial agents and chemotherapy. doi:10.1128/aac.00163-19

    DOI: 10.1128/aac.00163-19

    Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa (Journal article)

    Cojutti, P. G., Maximova, N., Schillani, G., Hope, W., & Pea, F. (2019). Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(6), 1648-1655. doi:10.1093/jac/dkz065

    DOI: 10.1093/jac/dkz065

    Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans. (Journal article)

    Bulitta, J. B., Hope, W. W., Eakin, A. E., Guina, T., Tam, V. H., Louie, A., . . . Hoover, J. L. (2019). Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(5). doi:10.1128/AAC.02307-18

    DOI: 10.1128/aac.02307-18

    Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis (Journal article)

    Stone, N. R. H., Rhodes, J., Fisher, M. C., Mfinanga, S., Kivuyo, S., Rugemalila, J., . . . Bicanic, T. (2019). Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. JOURNAL OF CLINICAL INVESTIGATION, 129(3), 999-1014. doi:10.1172/JCI124516

    DOI: 10.1172/JCI124516

    CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study (Journal article)

    Blassmann, U., Hope, W., Roehr, A. C., Frey, O. R., Vetter-Kerkhoff, C., Thon, N., . . . Huge, V. (2019). CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(4), 991-996. doi:10.1093/jac/dky543

    DOI: 10.1093/jac/dky543

    A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. (Journal article)

    Ngan, N. T. T., Mai, N. T. H., Tung, N. L. N., Lan, N. P. H., Tai, L. T. H., Phu, N. H., . . . Day, J. (2019). A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.. doi:10.12688/wellcomeopenres.15010.1

    DOI: 10.12688/wellcomeopenres.15010.1

    Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study. (Journal article)

    Hope, W., Johnstone, G., Cicconi, S., Felton, T., Goodwin, J., Whalley, S., . . . Neely, M. (2019). Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study.. Antimicrobial agents and chemotherapy. doi:10.1128/aac.02353-18

    DOI: 10.1128/aac.02353-18

    AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial (vol 19, 649, 2018) (Journal article)

    Lawrence, D. S., Youssouf, N., Molloy, S. F., Alanio, A., Alufandika, M., Boulware, D. R., . . . Jarvis, J. N. (2019). AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial (vol 19, 649, 2018). TRIALS, 20. doi:10.1186/s13063-018-3155-9

    DOI: 10.1186/s13063-018-3155-9

    Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials (Journal article)

    Andes, D. R., Ghannoum, M. A., Mukherjee, P. K., Kovanda, L. L., Lu, Q., Jones, M. E., . . . Hope, W. W. (2019). Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(1). doi:10.1128/AAC.01634-18

    DOI: 10.1128/AAC.01634-18

    2018

    Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis (vol 62, e02526-17, 2018) (Journal article)

    Stott, K. E., Beardsley, J., Whalley, S., Kibengo, F. M., Mai, N. T. H., Tung, N. L. N., . . . Day, J. (2018). Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis (vol 62, e02526-17, 2018). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(12). doi:10.1128/AAC.02249-18

    DOI: 10.1128/AAC.02249-18

    Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis (vol 62, e00885-18, 2018) (Journal article)

    Stott, K. E., Beardsley, J., Kolamunnage-Dona, R., Castelazo, A. S., Kibengo, F. M., Mai, N. T. H., . . . Hope, W. (2018). Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis (vol 62, e00885-18, 2018). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(12). doi:10.1128/AAC.02254-18

    DOI: 10.1128/AAC.02254-18

    AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial (Journal article)

    Lawrence, D. S., Youssouf, N., Molloy, S. L. F., Alanio, A., Alufandika, M., Boulware, D. R., . . . Jarvis, J. N. (2018). AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. TRIALS, 19. doi:10.1186/s13063-018-3026-4

    DOI: 10.1186/s13063-018-3026-4

    Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei. (Journal article)

    Le, T., Ly, V. T., Thu, N. T. M., Nguyen, A., Thanh, N. T., Chau, N. V. V., . . . Hope, W. (2019). Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(2). doi:10.1128/AAC.01739-18

    DOI: 10.1128/aac.01739-18

    Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies (Journal article)

    Cojutti, P. G., Candoni, A., Lazzarotto, D., Rabassi, N., Fanin, R., Hope, W., & Pea, F. (2018). Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84(11), 2544-2550. doi:10.1111/bcp.13707

    DOI: 10.1111/bcp.13707

    Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system (Journal article)

    Stott, K. E., & Hope, W. (2018). Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(8), 803-815. doi:10.1080/17425255.2018.1492551

    DOI: 10.1080/17425255.2018.1492551

    Short Course High-dose Liposomal Amphotericin B for HIV-associated Cryptococcal Meningitis: A phase-II Randomized Controlled Trial. (Journal article)

    Jarvis, J. N., Leeme, T. B., Molefi, M., Chofle, A. A., Bidwell, G., Tsholo, K., . . . Harrison, T. S. (2019). Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. CLINICAL INFECTIOUS DISEASES, 68(3), 393-401. doi:10.1093/cid/ciy515

    DOI: 10.1093/cid/ciy515

    Population pharmacokinetics and cerebrospinal fluid penetration of fluconazole in adults with cryptococcal meningitis. (Journal article)

    Stott, K. E., Beardsley, J., Kolamunnage-Dona, R., Castelazo, A. S., Kibengo, F. M., Mai, N. T. H., . . . Hope, W. (2018). Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(9). doi:10.1128/AAC.00885-18

    DOI: 10.1128/aac.00885-18

    Amphotericin B Deoxycholate in adults with Cryptococcal Meningitis; a Population Pharmacokinetic Model and Meta-Analysis of Outcomes. (Journal article)

    Stott, K. E., Beardsley, J., Whalley, S., Kibengo, F. M., Mai, N. T. H., Kolamunnage-Dona, R., . . . Day, J. (2018). Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.02526-17

    DOI: 10.1128/aac.02526-17

    Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance (Journal article)

    Cojutti, P. G., Barbarino, C., De Monte, A., Hope, W., & Pea, F. (2018). Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 74(8), 1091-1092. doi:10.1007/s00228-018-2465-x

    DOI: 10.1007/s00228-018-2465-x

    Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli (Journal article)

    Merino-Bohorquez, V., Docobo-Perez, F., Sojo, J., Morales, I., Lupion, C., Martin, D., . . . Rodriguez-Bano, J. (2018). Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli. CLINICAL MICROBIOLOGY AND INFECTION, 24(11), 1177-1183. doi:10.1016/j.cmi.2018.02.005

    DOI: 10.1016/j.cmi.2018.02.005

    A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants with Invasive Candidiasis. (Journal article)

    Jr, B. D. K., Kaufman, D. A., Hope, W. W., Smith, P. B., Arrieta, A., Manzoni, P., . . . Walsh, T. J. (2018). A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 37(10), 992-998. doi:10.1097/INF.0000000000001996

    DOI: 10.1097/inf.0000000000001996

    Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin. (Journal article)

    Rawson, T. M., Charani, E., Moore, L. S. P., Gilchrist, M., Georgiou, P., Hope, W., & Holmes, A. H. (2018). Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin. THERAPEUTIC DRUG MONITORING, 40(3), 315-321. doi:10.1097/FTD.0000000000000507

    DOI: 10.1097/ftd.0000000000000507

    Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. (Journal article)

    Box, H., Negri, C., Livermore, J., Whalley, S., Johnson, A., McEntee, L., . . . Hope, W. (2018). Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(5). doi:10.1128/AAC.02516-17

    DOI: 10.1128/aac.02516-17

    Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers (Journal article)

    Felton, T. W., Ogungbenro, K., Boselli, E., Hope, W. W., & Rodvold, K. A. (2018). Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(5), 1340-1347. doi:10.1093/jac/dkx541

    DOI: 10.1093/jac/dkx541

    Pharmacodynamics of Flubendazole for Cryptococcal Meningoencephalitis: Repurposing and Reformulation of an Anti-Parasitic Agent for a Neglected Fungal Disease. (Journal article)

    Nixon, G. L., McEntee, L., Johnson, A., Farrington, N., Whalley, S., Livermore, J., . . . Hope, W. (2018). Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(4). doi:10.1128/AAC.01909-17

    DOI: 10.1128/aac.01909-17

    Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp. (Journal article)

    Cojutti, P. G., Lugano, M., Righi, E., Della Rocca, G., Bassetti, M., Hope, W., & Pea, F. (2018). Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 74(11), 1449-1459. doi:10.1007/s00228-018-2526-1

    DOI: 10.1007/s00228-018-2526-1

    2017

    Delivering precision antimicrobial therapy through closed-loop control systems. (Journal article)

    Rawson, T. M., O'Hare, D., Herrero, P., Sharma, S., Moore, L. S. P., de Barra, E., . . . Holmes, A. H. (2018). Delivering precision antimicrobial therapy through closed-loop control systems. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(4), 835-843. doi:10.1093/jac/dkx458

    DOI: 10.1093/jac/dkx458

    Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial (Journal article)

    Kontoyiannis, D. P., Selleslag, D., Mullane, K., Cornely, O. A., Hope, W., Lortholary, O., . . . Patterson, T. F. (2018). Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(3), 757-763. doi:10.1093/jac/dkx423

    DOI: 10.1093/jac/dkx423

    Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung (Journal article)

    Rodvold, K. A., Hope, W. W., & Boyd, S. E. (2017). Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. CURRENT OPINION IN PHARMACOLOGY, 36, 114-123. doi:10.1016/j.coph.2017.09.019

    DOI: 10.1016/j.coph.2017.09.019

    Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats (Journal article)

    Schmitt-Hoffmann, A. -H., Kato, K., Townsend, R., Potchoiba, M. J., Hope, W. W., Andes, D., . . . Schneidkraut, M. J. (2017). Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(12). doi:10.1128/AAC.01292-17

    DOI: 10.1128/AAC.01292-17

    Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. (Journal article)

    Desai, A. V., Kovanda, L. L., Hope, W. W., Andes, D., Mouton, J. W., Kowalski, D. L., . . . Bonate, P. L. (2017). Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(12). doi:10.1128/AAC.01034-17

    DOI: 10.1128/aac.01034-17

    Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus. (Journal article)

    Negri, C. E., Johnson, A., McEntee, L., Box, H., Whalley, S., Schwartz, J. A., . . . Hope, W. W. (2018). Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus. JOURNAL OF INFECTIOUS DISEASES, 217(7), 1118-1127. doi:10.1093/infdis/jix479

    Pharmacodynamics of teicoplanin against MRSA (Journal article)

    Ramos-Martin, V., Johnson, A., McEntee, L., Farrington, N., Padmore, K., Cojutti, P., . . . Hope, W. W. (2017). Pharmacodynamics of teicoplanin against MRSA. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(12), 3382-3389. doi:10.1093/jac/dkx289

    DOI: 10.1093/jac/dkx289

    Combination therapy for carbapenemase-producing Enterobacteriaceae: INCREMENT-al effect on resistance remains unclear (Journal article)

    Boyd, S. E., Moore, L. S. P., Rawson, T. M., Hope, W. W., & Holmes, A. H. (2017). Combination therapy for carbapenemase-producing Enterobacteriaceae: INCREMENT-al effect on resistance remains unclear. LANCET INFECTIOUS DISEASES, 17(9), 899-+. doi:10.1016/S1473-3099(17)30450-4

    DOI: 10.1016/S1473-3099(17)30450-4

    Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. (Journal article)

    Hope, W. W., McEntee, L., Livermore, J., Whalley, S., Johnson, A., Farrington, N., . . . Rex, J. H. (2017). Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. MBIO, 8(4). doi:10.1128/mBio.01157-17

    DOI: 10.1128/mbio.01157-17

    Tools for the Individualized Therapy of Teicoplanin for Neonates and Children. (Journal article)

    Ramos-Martin, V., Neely, M. N., Padmore, K., Peak, M., Beresford, M. W., Turner, M. A., . . . Hope, W. W. (2017). Tools for the Individualized Therapy of Teicoplanin for Neonates and Children. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(10). doi:10.1128/AAC.00707-17

    DOI: 10.1128/aac.00707-17

    Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis. (Journal article)

    Petraitis, V., Petraitiene, R., McCarthy, M. W., Kovanda, L. L., Zaw, M. H., Hussain, K., . . . Walsh, T. J. (2017). Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(9). doi:10.1128/AAC.00305-17

    DOI: 10.1128/aac.00305-17

    Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis. (Journal article)

    Petraitis, V., Petraitiene, R., Hope, W. W., & Walsh, T. J. (2017). Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis.. Methods in molecular biology (Clifton, N.J.), 1625, 259-277. doi:10.1007/978-1-4939-7104-6_18

    DOI: 10.1007/978-1-4939-7104-6_18

    PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS DEMERSUS) AFTER SINGLE AND MULTIPLE DOSES. (Journal article)

    Hyatt, M. W., Wiederhold, N. P., Hope, W. W., & Stott, K. E. (2017). PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS DEMERSUS) AFTER SINGLE AND MULTIPLE DOSES. JOURNAL OF ZOO AND WILDLIFE MEDICINE, 48(2), 352-362. doi:10.1638/2016-0160R2.1

    DOI: 10.1638/2016-0160r2.1

    Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response (Journal article)

    Kovanda, L. L., Kolamunnage-Dona, R., Neely, M., Maertens, J., Lee, M., & Hope, W. W. (2017). Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. CLINICAL INFECTIOUS DISEASES, 64(11), 1557-1563. doi:10.1093/cid/cix198

    DOI: 10.1093/cid/cix198

    Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. (Journal article)

    Cojutti, P. G., Candoni, A., Ramos-Martin, V., lazzarotto, D., Zannier, M. E., Fanin, R., . . . Pea, F. (2017). Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(8), 2342-2350. doi:10.1093/jac/dkx140

    DOI: 10.1093/jac/dkx140

    The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. (Journal article)

    Li, G., Standing, J. F., Bielicki, J., Hope, W., van den Anker, J., Heath, P. T., & Sharland, M. (2017). The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. DRUGS, 77(9), 941-950. doi:10.1007/s40265-017-0745-x

    DOI: 10.1007/s40265-017-0745-x

    Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. (Journal article)

    Stott, K. E., & Hope, W. W. (2017). Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72, I12-I18. doi:10.1093/jac/dkx029

    DOI: 10.1093/jac/dkx029

    Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis (Journal article)

    Kovanda, L. L., Desai, A. V., & Hope, W. W. (2017). Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 44(2), 143-151. doi:10.1007/s10928-017-9509-1

    DOI: 10.1007/s10928-017-9509-1

    Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. (Journal article)

    Lestner, J., McEntee, L., Johnson, A., Livermore, J., Whalley, S., Schwartz, J., . . . Hope, W. (2017). Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(6). doi:10.1128/AAC.00090-17

    DOI: 10.1128/aac.00090-17

    Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole (Journal article)

    Kovanda, L. L., Marty, F. M., Maertens, J., Desai, A. V., Lademacher, C., Engelhardt, M., . . . Hope, W. W. (2017). Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(6). doi:10.1128/AAC.00101-17

    DOI: 10.1128/AAC.00101-17

    A systematic review of clinical decision support systems for antimicrobial management: are we failing to investigate these interventions appropriately? (Journal article)

    Rawson, T. M., Moore, L. S. P., Hernandez, B., Charani, E., Castro-Sanchez, E., Herrero, P., . . . Holmes, A. H. (2017). A systematic review of clinical decision support systems for antimicrobial management: are we failing to investigate these interventions appropriately?. CLINICAL MICROBIOLOGY AND INFECTION, 23(8), 524-532. doi:10.1016/j.cmi.2017.02.028

    DOI: 10.1016/j.cmi.2017.02.028

    Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function (Journal article)

    Cojutti, P. G., Ramos-Martin, V., Schiavon, I., Rossi, P., Baraldo, M., Hope, W., & Pea, F. (2017). Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(3). doi:10.1128/AAC.02134-16

    DOI: 10.1128/AAC.02134-16

    Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment (Journal article)

    Rawson, T. M., Charani, E., Moore, L. S. P., Herrero, P., Baik, J. S., Philip, A., . . . Holmes, A. H. (2017). Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment. JOURNAL OF INFECTION, 74(3), 320-324. doi:10.1016/j.jinf.2016.12.011

    DOI: 10.1016/j.jinf.2016.12.011

    Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV plus Population Is Not Related to Antiretroviral Therapy (Journal article)

    Torok, M. E., Aljayyoussi, G., Waterhouse, D., Chau, T. T. H., Mai, N. T. H., Phu, N. H., . . . Ward, S. A. (2018). Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV plus Population Is Not Related to Antiretroviral Therapy. CLINICAL PHARMACOLOGY & THERAPEUTICS, 103(3), 449-457. doi:10.1002/cpt.646

    DOI: 10.1002/cpt.646

    Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients (Journal article)

    Seibel, N. L., Shad, A. T., Bekersky, I., Groll, A. H., Gonzalez, C., Wood, L. V., . . . Walsh, T. J. (2017). Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(2). doi:10.1128/AAC.01477-16

    DOI: 10.1128/AAC.01477-16

    Haloprogin (Chapter)

    Ramos-Martín, V., & Hope, W. (2017). Haloprogin. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 2933-2935). doi:10.1201/9781315152110

    DOI: 10.1201/9781315152110

    Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy (Journal article)

    Sime, F. B., Johnson, A., Whalley, S., Santoyo-Castelazo, A., Montgomery, A. B., Walters, K. A., . . . Roberts, J. A. (2017). Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi:10.1128/AAC.01763-16

    DOI: 10.1128/AAC.01763-16

    2016

    Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study (Journal article)

    Blassmann, U., Roehr, A. C., Frey, O. R., Vetter-Kerkhoff, C., Thon, N., Hope, W., . . . Huge, V. (2016). Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. CRITICAL CARE, 20. doi:10.1186/s13054-016-1523-y

    DOI: 10.1186/s13054-016-1523-y

    Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children (Journal article)

    Lestner, J. M., Groll, A. H., Aljayyoussi, G., Seibel, N. L., Shad, A., Gonzalez, C., . . . Hope, W. W. (2016). Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(12), 7340-7346. doi:10.1128/AAC.01427-16

    DOI: 10.1128/AAC.01427-16

    F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase (Journal article)

    Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., . . . Birch, M. (2016). F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 113(45), 12809-12814. doi:10.1073/pnas.1608304113

    DOI: 10.1073/pnas.1608304113

    Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality (Journal article)

    Hope, W., Drusano, G. L., & Rex, J. H. (2016). Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(11), 3008-3019. doi:10.1093/jac/dkw298

    DOI: 10.1093/jac/dkw298

    Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy (Journal article)

    Ramos-Martin, V., Neely, M. N., McGowan, P., Siner, S., Padmore, K., Peak, M., . . . Hope, W. W. (2016). Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(11), 3168-3178. doi:10.1093/jac/dkw295

    DOI: 10.1093/jac/dkw295

    Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study) (Journal article)

    Kovanda, L. L., Desai, A. V., Lu, Q., Townsend, R. W., Akhtar, S., Bonate, P., & Hope, W. W. (2016). Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(8), 4568-4576. doi:10.1128/AAC.00514-16

    DOI: 10.1128/AAC.00514-16

    Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial (Journal article)

    Hope, W. W., Walsh, T. J., Goodwin, J., Peloquin, C. A., Howard, A., Kurtzberg, J., . . . Clinical, B. M. T. (2016). Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(8), 2234-2240. doi:10.1093/jac/dkw127

    DOI: 10.1093/jac/dkw127

    Isavuconazonium sulfate: A new agent for the treatment of invasive aspergillosis and invasive mucormycosis (Journal article)

    Kovanda, L. L., Maher, R., & Hope, W. W. (2016). Isavuconazonium sulfate: A new agent for the treatment of invasive aspergillosis and invasive mucormycosis. Expert Review of Clinical Pharmacology, 9(7), 887-897. doi:10.1080/17512433.2016.1185361

    DOI: 10.1080/17512433.2016.1185361

    Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints (Journal article)

    Kovanda, L. L., Petraitiene, R., Petraitis, V., Walsh, T. J., Desai, A., Bonate, P., & Hope, W. W. (2016). Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(7), 1885-1891. doi:10.1093/jac/dkw098

    DOI: 10.1093/jac/dkw098

    Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy (Journal article)

    Huurneman, L. J., Neely, M., Veringa, A., Docobo Perez, F., Ramos-Martin, V., Tissing, W. J., . . . Hope, W. (2016). Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(4), 2336-2342. doi:10.1128/AAC.03023-15

    DOI: 10.1128/AAC.03023-15

    Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates (Journal article)

    Ramos-Martin, V., Johnson, A., Livermore, J., McEntee, L., Goodwin, J., Whalley, S., . . . Hope, W. W. (2016). Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 992-1002. doi:10.1093/jac/dkv451

    DOI: 10.1093/jac/dkv451

    Liposomal Amphotericin B (AmBisome((R))): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions (Journal article)

    Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016). Liposomal Amphotericin B (AmBisome((R))): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. DRUGS, 76(4), 485-500. doi:10.1007/s40265-016-0538-7

    DOI: 10.1007/s40265-016-0538-7

    Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1 (Journal article)

    Drusano, G. L., Louie, A., MacGowan, A., & Hope, W. (2016). Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(3), 1183-1193. doi:10.1128/AAC.02177-15

    DOI: 10.1128/AAC.02177-15

    Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2 (Journal article)

    Drusano, G. L., Hope, W., MacGowan, A., & Louie, A. (2016). Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(3), 1194-1201. doi:10.1128/AAC.02231-15

    DOI: 10.1128/AAC.02231-15

    Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial (Journal article)

    Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., . . . Ullmann, A. J. (2016). Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. LANCET, 387(10020), 760-769. doi:10.1016/S0140-6736(15)01159-9

    DOI: 10.1016/S0140-6736(15)01159-9

    Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis (Journal article)

    Petraitis, V., Petraitiene, R., Moradi, P. W., Strauss, G. E., Katragkou, A., Kovanda, L. L., . . . Walsh, T. J. (2016). Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(5), 2718-2726. doi:10.1128/AAC.02665-15

    DOI: 10.1128/AAC.02665-15

    Antifungal Pharmacokinetics and Pharmacodynamics (Chapter)

    Hope, W. W., & Andes, D. R. (2016). Antifungal Pharmacokinetics and Pharmacodynamics. In J. C. Rotschafer, D. R. Andes, & K. A. Rodvold (Eds.), Antbiotic Pharmacodynamics (pp. 369). New York: Humana Press.

    Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits (Journal article)

    Petraitiene, R., Petraitis, V., Hope, W. W., & Walsh, T. J. (2015). Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits. CLINICAL INFECTIOUS DISEASES, 61, S643-S651. doi:10.1093/cid/civ817

    DOI: 10.1093/cid/civ817

    Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy (Journal article)

    Bustinduy, A. L., Waterhouse, D., de Sousa-Figueiredo, J. C., Roberts, S. A., Atuhaire, A., Van Dam, G. J., . . . Stothard, J. R. (2016). Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy. MBIO, 7(4). doi:10.1128/mBio.00227-16

    DOI: 10.1128/mBio.00227-16

    2015

    Clinical pharmacology of antifungal agents in pediatrics: children are not small adults (Journal article)

    Ramos-Martin, V., O'Connor, O., & Hope, W. (2015). Clinical pharmacology of antifungal agents in pediatrics: children are not small adults. CURRENT OPINION IN PHARMACOLOGY, 24, 128-134. doi:10.1016/j.coph.2015.08.009

    DOI: 10.1016/j.coph.2015.08.009

    Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance (Journal article)

    Docobo-Perez, F., Drusano, G. L., Johnson, A., Goodwin, J., Whalley, S., Ramos-Martin, V., . . . Hope, W. W. (2015). Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(9), 5602-5610. doi:10.1128/AAC.00752-15

    DOI: 10.1128/AAC.00752-15

    Linezolid underexposure in a patient co-treated with venlafaxine (Journal article)

    Cojutti, P., Crapis, M., Bassetti, M., Hope, W., & Pea, F. (2015). Linezolid underexposure in a patient co-treated with venlafaxine. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 71(10), 1285-1286. doi:10.1007/s00228-015-1922-z

    DOI: 10.1007/s00228-015-1922-z

    Therapeutic drug monitoring of the beta-lactam antibiotics: what is the evidence and which patients should we be using it for? (Journal article)

    Huttner, A., Harbarth, S., Hope, W. W., Lipman, J., & Roberts, J. A. (2015). Therapeutic drug monitoring of the beta-lactam antibiotics: what is the evidence and which patients should we be using it for?. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3178-3183. doi:10.1093/jac/dkv201

    DOI: 10.1093/jac/dkv201

    Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis (Journal article)

    Grau, S., Luque, S., Campillo, N., Samso, E., Rodriguez, U., Garcia-Bernedo, C. A., . . . Roberts, J. A. (2015). Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2854-2861. doi:10.1093/jac/dkv173

    DOI: 10.1093/jac/dkv173

    Achieving Target Voriconazole Concentrations More Accurately in Children and Adolescents (Journal article)

    Neely, M., Margol, A., Fu, X., van Guilder, M., Bayard, D., Schumitzky, A., . . . Hope, W. (2015). Achieving Target Voriconazole Concentrations More Accurately in Children and Adolescents. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(6), 3090-3097. doi:10.1128/AAC.00032-15

    DOI: 10.1128/AAC.00032-15

    Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus (Journal article)

    Al-Nakeeb, Z., Petraitis, V., Goodwin, J., Petraitiene, R., Walsh, T. J., & Hope, W. W. (2015). Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(5), 2735-2745. doi:10.1128/AAC.04723-14

    DOI: 10.1128/AAC.04723-14

    Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients (Journal article)

    Roberts, J. A., Udy, A. A., Jarrett, P., Wallis, S. C., Hope, W. W., Sharma, R., . . . Lipman, J. (2015). Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(5), 1495-1502. doi:10.1093/jac/dku564

    DOI: 10.1093/jac/dku564

    AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial (Journal article)

    Molefi, M., Chofle, A. A., Molloy, S. F., Kalluvya, S., Changalucha, J. M., Cainelli, F., . . . Jarvis, J. N. (2015). AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. TRIALS, 16. doi:10.1186/s13063-015-0799-6

    DOI: 10.1186/s13063-015-0799-6

    Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development (Journal article)

    Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Hope, W. W., & Roberts, J. A. (2015). Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 36(1), 136-153. doi:10.1055/s-0034-1398490

    DOI: 10.1055/s-0034-1398490

    Guidelines need controls (Journal article)

    Raoult, D., Hope, W., & Kahlmeter, G. (2015). Guidelines need controls. CLINICAL MICROBIOLOGY AND INFECTION, 21(12), 1043-1044. doi:10.1016/j.cmi.2015.09.010

    DOI: 10.1016/j.cmi.2015.09.010

    Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis (Journal article)

    Box, H., Livermore, J., Johnson, A., McEntee, L., Felton, T. W., Whalley, S., . . . Hope, W. W. (2016). Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(1), 278-287. doi:10.1128/AAC.01364-15

    DOI: 10.1128/AAC.01364-15

    2014

    An invertebrate model to evaluate virulence in Aspergillus fumigatus: The role of azole resistance (Journal article)

    Gomez-Lopez, A., Forastiero, A., Cendejas-Bueno, E., Gregson, L., Mellado, E., Howard, S. J., . . . Cuenca-Estrella, M. (2014). An invertebrate model to evaluate virulence in Aspergillus fumigatus: The role of azole resistance. MEDICAL MYCOLOGY, 52(3), 311-319. doi:10.1093/mmy/myt022

    DOI: 10.1093/mmy/myt022

    Changes in the Incidence of Candidiasis in Neonatal Intensive Care Units (Journal article)

    Aliaga, S., Clark, R. H., Laughon, M., Walsh, T. J., Hope, W. W., Benjamin, D. K., . . . Smith, P. B. (2014). Changes in the Incidence of Candidiasis in Neonatal Intensive Care Units. PEDIATRICS, 133(2), 236-242. doi:10.1542/peds.2013-0671

    DOI: 10.1542/peds.2013-0671

    Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients (Journal article)

    Wong, G., Farkas, A., Sussman, R., Daroczi, G., Hope, W. W., Lipman, J., & Roberts, J. A. (2015). Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(3), 1411-1417. doi:10.1128/AAC.04001-14

    DOI: 10.1128/AAC.04001-14

    ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi (Journal article)

    Chowdhary, A., Meis, J. F., Guarro, J., de Hoog, G. S., Kathuria, S., Arendrup, M. C., . . . Cuenca-Estrella, M. (2014). ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. CLINICAL MICROBIOLOGY AND INFECTION, 20, 47-75. doi:10.1111/1469-0691.12515

    DOI: 10.1111/1469-0691.12515

    ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others (Journal article)

    Tortorano, A. M., Richardson, M., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., . . . Microbiol, E. S. C. (2014). ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. CLINICAL MICROBIOLOGY AND INFECTION, 20, 27-46. doi:10.1111/1469-0691.12465

    DOI: 10.1111/1469-0691.12465

    ESCMID dagger and ECMM double dagger joint clinical guidelines for the diagnosis and management of mucormycosis 2013 (Journal article)

    Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., . . . Med, E. C. (2014). ESCMID dagger and ECMM double dagger joint clinical guidelines for the diagnosis and management of mucormycosis 2013. CLINICAL MICROBIOLOGY AND INFECTION, 20, 5-26. doi:10.1111/1469-0691.12371

    DOI: 10.1111/1469-0691.12371

    ESCMID dagger and ECMM double dagger joint clinical guidelines for the diagnosis and management of rare invasive yeast infections (Journal article)

    Arendrup, M. C., Boekhout, T., Akova, M., Meis, J. F., Cornely, O. A., Lortholary, O., . . . ECMM. (2014). ESCMID dagger and ECMM double dagger joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. CLINICAL MICROBIOLOGY AND INFECTION, 20, 76-98. doi:10.1111/1469-0691.12360

    DOI: 10.1111/1469-0691.12360

    EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole (Journal article)

    Arendrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., Hope, W. W., & Antimicrobial, E. C. (2014). EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole. MYCOSES, 57(6), 377-379. doi:10.1111/myc.12170

    DOI: 10.1111/myc.12170

    Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days (Journal article)

    Livermore, J., Howard, S. J., Sharp, A. D., Goodwin, J., Gregson, L., Felton, T., . . . Hope, W. W. (2014). Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days. MBIO, 5(1). doi:10.1128/mBio.00725-13

    DOI: 10.1128/mBio.00725-13

    First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro-In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole (Journal article)

    Zhao, W., Le Guellec, C., Jr, B. D. K., Hope, W. W., Bourgeois, T., Watt, K. M., . . . Jacqz-Aigrain, E. (2014). First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro-In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole. CLINICAL PHARMACOKINETICS, 53(11), 1005-1018. doi:10.1007/s40262-014-0169-7

    DOI: 10.1007/s40262-014-0169-7

    Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation (Journal article)

    Groll, A. H., Castagnola, E., Cesaro, S., Dalle, J. -H., Engelhard, D., Hope, W., . . . ELN. (2014). Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. LANCET ONCOLOGY, 15(8), E327-E340. doi:10.1016/S1470-2045(14)70017-8

    DOI: 10.1016/S1470-2045(14)70017-8

    Gene Expression Profiles of Human Dendritic Cells Interacting with Aspergillus fumigatus in a Bilayer Model of the Alveolar Epithelium/Endothelium Interface (Journal article)

    Morton, C. O., Fliesser, M., Dittrich, M., Mueller, T., Bauer, R., Kneitz, S., . . . Loeffler, J. (2014). Gene Expression Profiles of Human Dendritic Cells Interacting with Aspergillus fumigatus in a Bilayer Model of the Alveolar Epithelium/Endothelium Interface. PLOS ONE, 9(5). doi:10.1371/journal.pone.0098279

    DOI: 10.1371/journal.pone.0098279

    How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it? (Journal article)

    Felton, T. W., Hope, W. W., & Roberts, J. A. (2014). How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 79(4), 441-447. doi:10.1016/j.diagmicrobio.2014.04.007

    DOI: 10.1016/j.diagmicrobio.2014.04.007

    Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions (Journal article)

    Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., . . . Microbiology, E. S. C. (2014). Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. LANCET INFECTIOUS DISEASES, 14(6), 498-509. doi:10.1016/S1473-3099(14)70036-2

    DOI: 10.1016/S1473-3099(14)70036-2

    Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy (Journal article)

    Felton, T. W., Roberts, J. A., Lodise, T. P., Van Guilder, M., Boselli, E., Neely, M. N., & Hope, W. W. (2014). Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(7), 4094-4102. doi:10.1128/AAC.02664-14

    DOI: 10.1128/AAC.02664-14

    Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents (Journal article)

    Hope, W. W., Kaibara, A., Roy, M., Arrieta, A., Azie, N., Kovanda, L. L., & Jr, B. D. K. (2015). Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(2), 905-913. doi:10.1128/AAC.03736-14

    DOI: 10.1128/AAC.03736-14

    Population Pharmacokinetics of Teicoplanin in Children (Journal article)

    Ramos-Martin, V., Paulus, S., Siner, S., Scott, E., Padmore, K., Newland, P., . . . Hope, W. W. (2014). Population Pharmacokinetics of Teicoplanin in Children. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(11), 6920-6927. doi:10.1128/AAC.03685-14

    DOI: 10.1128/AAC.03685-14

    Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients (Journal article)

    Felton, T. W., McCalman, K., Malagon, I., Isalska, B., Whalley, S., Goodwin, J., . . . Hope, W. W. (2014). Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(4), 438-448. doi:10.1038/clpt.2014.131

    DOI: 10.1038/clpt.2014.131

    Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology (Journal article)

    Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014). Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(5), 1162-1176. doi:10.1093/jac/dkt508

    DOI: 10.1093/jac/dkt508

    Tissue Penetration of Antifungal Agents (Journal article)

    Felton, T., Troke, P. F., & Hope, W. W. (2014). Tissue Penetration of Antifungal Agents. CLINICAL MICROBIOLOGY REVIEWS, 27(1), 68-88. doi:10.1128/CMR.00046-13

    DOI: 10.1128/CMR.00046-13

    2013

    Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in Pseudomonas aeruginosa (Journal article)

    Felton, T. W., Goodwin, J., O'Connor, L., Sharp, A., Gregson, L., Livermore, J., . . . Hope, W. W. (2013). Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in Pseudomonas aeruginosa. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(12), 5811-5819. doi:10.1128/AAC.00867-13

    DOI: 10.1128/AAC.00867-13

    EUCAST Technical Note on Voriconazole and Aspergillus spp. (Journal article)

    Hope, W. W., Cuenca-Estrella, M., Lass-Floerl, C., Arendrup, M. C., & Antimicrobial, E. C. (2013). EUCAST Technical Note on Voriconazole and Aspergillus spp.. CLINICAL MICROBIOLOGY AND INFECTION, 19(6), E278-E280. doi:10.1111/1469-0691.12148

    DOI: 10.1111/1469-0691.12148

    Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. (Journal article)

    Arendrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., & Hope, W. W. (2013). Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.. DRUG RESISTANCE UPDATES, 16(6), 81-95. doi:10.1016/j.drup.2014.01.001

    DOI: 10.1016/j.drup.2014.01.001

    In Vitro Susceptibility of Aspergillus fumigatus to Isavuconazole: Correlation with Itraconazole, Voriconazole, and Posaconazole (Journal article)

    Gregson, L., Goodwin, J., Johnson, A., McEntee, L., Moore, C. B., Richardson, M., . . . Howard, S. J. (2013). In Vitro Susceptibility of Aspergillus fumigatus to Isavuconazole: Correlation with Itraconazole, Voriconazole, and Posaconazole. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5778-5780. doi:10.1128/AAC.01141-13

    DOI: 10.1128/AAC.01141-13

    Invasive fungal infections (Journal article)

    Hope, W., Natarajan, P., & Goodwin, L. (2013). Invasive fungal infections. CLINICAL MEDICINE, 13(5), 507-510. doi:10.7861/clinmedicine.13-5-507

    DOI: 10.7861/clinmedicine.13-5-507

    Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections (Journal article)

    Lestner, J., & Hope, W. W. (2013). Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 9(7), 911-926. doi:10.1517/17425255.2013.794785

    DOI: 10.1517/17425255.2013.794785

    Opinion: The Pharmacometrics of Infectious Disease (Journal article)

    Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: The Pharmacometrics of Infectious Disease. CPT: Pharmacometrics & Systems Pharmacology, 2(8), e70. doi:10.1038/psp.2013.46

    DOI: 10.1038/psp.2013.46

    Opinion: the pharmacometrics of infectious disease. (Journal article)

    Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: the pharmacometrics of infectious disease.. CPT: pharmacometrics & systems pharmacology, 2, e70. doi:10.1038/psp.2013.46

    DOI: 10.1038/psp.2013.46

    Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients (Journal article)

    O'Connor, L., Livermore, J., Sharp, A. D., Goodwin, J., Gregson, L., Howard, S. J., . . . Hope, W. W. (2013). Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients. JOURNAL OF INFECTIOUS DISEASES, 208(2), 351-361. doi:10.1093/infdis/jit164

    DOI: 10.1093/infdis/jit164

    Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and In Vitro Susceptibility Breakpoints (Journal article)

    Sudan, A., Livermore, J., Howard, S. J., Al-Nakeeb, Z., Sharp, A., Goodwin, J., . . . Hope, W. W. (2013). Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and In Vitro Susceptibility Breakpoints. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(6), 2793-2800. doi:10.1128/AAC.00216-13

    DOI: 10.1128/AAC.00216-13

    Software for Dosage Individualization of Voriconazole for Immunocompromised Patients (Journal article)

    Hope, W. W., VanGuilder, M., Donnelly, J. P., Blijlevens, N. M. A., Bruggemann, R. J. M., Jelliffe, R. W., & Neely, M. N. (2013). Software for Dosage Individualization of Voriconazole for Immunocompromised Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(4), 1888-1894. doi:10.1128/AAC.02025-12

    DOI: 10.1128/AAC.02025-12

    The pharmacometrics of infectious diseases (Journal article)

    Davies, G. R., Khoo, S. H., & Hope, W. (2013). The pharmacometrics of infectious diseases. CPT: Pharmacometrics and systems pharmacology, 2, e70. Retrieved from cpt:%20pharmacomet.%20syst.%20pharmacol.%202:%20e70;%20doi:10.1038/psp.2013.46

    2012

    ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures (Journal article)

    Cuenca-Estrella, M., Verweij, P. E., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Donnelly, J. P., . . . Microbiology, E. S. C. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. CLINICAL MICROBIOLOGY AND INFECTION, 18, 9-18. doi:10.1111/1469-0691.12038

    DOI: 10.1111/1469-0691.12038

    Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology (vol 50, pg 2509, 2012) (Journal article)

    Alastruey-Izquierdo, A., Gomez-Lopez, A., Arendrup, M. C., Lass-Florl, C., Hope, W. W., Perlin, D. S., . . . Cuenca-Estrella, M. (2012). Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology (vol 50, pg 2509, 2012). JOURNAL OF CLINICAL MICROBIOLOGY, 50(9), 3149. doi:10.1128/JCM.01843-12

    DOI: 10.1128/JCM.01843-12

    Anidulafungin for Neonatal Hematogenous Candida Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach (Journal article)

    Warn, P. A., Livermore, J., Howard, S., Felton, T. W., Sharp, A., Gregson, L., . . . Hope, W. W. (2012). Anidulafungin for Neonatal Hematogenous Candida Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 708-714. doi:10.1128/AAC.05826-11

    DOI: 10.1128/AAC.05826-11

    Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective (Journal article)

    Lestner, J. M., Smith, P. B., Cohen-Wolkowiez, M., Jr, B. D. K., & Hope, W. W. (2013). Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 75(6), 1381-1395. doi:10.1111/bcp.12025

    DOI: 10.1111/bcp.12025

    Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions (Journal article)

    Hope, W. W., Howard, S. J., & Felton, T. W. (2012). Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions. MYCOSES, 55, 33-38. doi:10.1111/j.1439-0507.2011.02114.x

    DOI: 10.1111/j.1439-0507.2011.02114.x

    Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant Aspergillus fumigatus in an In Vitro Model of Invasive Pulmonary Aspergillosis (Journal article)

    Jeans, A. R., Howard, S. J., Al-Nakeeb, Z., Goodwin, J., Gregson, L., Warn, P. A., & Hope, W. W. (2012). Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant Aspergillus fumigatus in an In Vitro Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(10), 5180-5185. doi:10.1128/AAC.01111-12

    DOI: 10.1128/AAC.01111-12

    Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. (Journal article)

    Alastruey-Izquierdo, A., Gómez-López, A., Arendrup, M. C., Lass-Florl, C., Hope, W. W., Perlin, D. S., . . . Cuenca-Estrella, M. (2012). Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology.. Journal of clinical microbiology, 50(7), 2509-2512. doi:10.1128/JCM.00791-12

    DOI: 10.1128/JCM.00791-12

    Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations (Journal article)

    Arendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012). Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(5), 2435-2442. doi:10.1128/AAC.06369-11

    DOI: 10.1128/AAC.06369-11

    Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin (Journal article)

    Slater, J. L., Howard, S. J., Sharp, A., Goodwin, J., Gregson, L. M., Alastruey-Izquierdo, A., . . . Hope, W. W. (2011). Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(7), 3075-3083. doi:10.1128/AAC.01686-10

    DOI: 10.1128/AAC.01686-10

    ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT) (Journal article)

    Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., . . . Microbiology, E. S. C. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). CLINICAL MICROBIOLOGY AND INFECTION, 18, 53-67. doi:10.1111/1469-0691.12041

    DOI: 10.1111/1469-0691.12041

    ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases (Journal article)

    Ullmann, A. J., Cornely, O. A., Donnelly, J. P., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., . . . Microbiology, E. S. C. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. CLINICAL MICROBIOLOGY AND INFECTION, 18, 1-8. doi:10.1111/1469-0691.12037

    DOI: 10.1111/1469-0691.12037

    ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients (Journal article)

    Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., . . . Microbiology, E. S. C. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. CLINICAL MICROBIOLOGY AND INFECTION, 18, 19-37. doi:10.1111/1469-0691.12039

    DOI: 10.1111/1469-0691.12039

    ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS (Journal article)

    Lortholary, O., Petrikkos, G., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., . . . Microbiology, E. S. C. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. CLINICAL MICROBIOLOGY AND INFECTION, 18, 68-77. doi:10.1111/1469-0691.12042

    DOI: 10.1111/1469-0691.12042

    ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. (Journal article)

    Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., . . . Microbiology, E. S. C. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.. CLINICAL MICROBIOLOGY AND INFECTION, 18, 38-52. doi:10.1111/1469-0691.12040

    DOI: 10.1111/1469-0691.12040

    EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole (Journal article)

    Arendrup, M. C., Cuenca-Estrella, M., Lass-Floel, C., Hope, W. W., & Suscep, E. C. A. (2012). EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole. CLINICAL MICROBIOLOGY AND INFECTION, 18(7), E248-E250. doi:10.1111/j.1469-0691.2012.03890.x

    DOI: 10.1111/j.1469-0691.2012.03890.x

    EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST) (Journal article)

    Arendrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., Hope, W., & EUCAST-AFST. (2012). EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). CLINICAL MICROBIOLOGY AND INFECTION, 18(7), E246-E247. doi:10.1111/j.1469-0691.2012.03880.x

    DOI: 10.1111/j.1469-0691.2012.03880.x

    Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections (Journal article)

    Livermore, J., & Hope, W. (2012). Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 8(6), 759-765. doi:10.1517/17425255.2012.683859

    DOI: 10.1517/17425255.2012.683859

    In vitro model of invasive pulmonary aspergillosis in the human alveolus. (Journal article)

    Gregson, L., Hope, W. W., & Howard, S. J. (2012). In vitro model of invasive pulmonary aspergillosis in the human alveolus.. Methods in molecular biology (Clifton, N.J.), 845, 361-367. doi:10.1007/978-1-61779-539-8_24

    DOI: 10.1007/978-1-61779-539-8_24

    Isolation of Aspergillus species from the airway of lung transplant recipients is associated with excess mortality (Journal article)

    Felton, T. W., Roberts, S. A., Isalska, B., Brennan, S., Philips, A., Whiteside, S., . . . Hope, W. W. (2012). Isolation of Aspergillus species from the airway of lung transplant recipients is associated with excess mortality. JOURNAL OF INFECTION, 65(4), 350-356. doi:10.1016/j.jinf.2012.07.008

    DOI: 10.1016/j.jinf.2012.07.008

    Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients (Journal article)

    Troke, P. F., Hockey, H. P., & Hope, W. W. (2011). Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(10), 4782-4788. doi:10.1128/AAC.01083-10

    DOI: 10.1128/AAC.01083-10

    Optimizing Micafungin Dosing in Children (Journal article)

    Zhao, W., Hope, W. W., Manzoni, P., & Jacqz-Aigrain, E. (2012). Optimizing Micafungin Dosing in Children. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 31(11), 1211-1212. doi:10.1097/INF.0b013e3182624bac

    DOI: 10.1097/INF.0b013e3182624bac

    Pharmacodynamics of Itraconazole against Aspergillus fumigatus in an In Vitro Model of the Human Alveolus: Perspectives on the Treatment of Triazole-Resistant Infection and Utility of Airway Administration (Journal article)

    Al-Nakeeb, Z., Sudan, A., Jeans, A. R., Gregson, L., Goodwin, J., Warn, P. A., . . . Hope, W. W. (2012). Pharmacodynamics of Itraconazole against Aspergillus fumigatus in an In Vitro Model of the Human Alveolus: Perspectives on the Treatment of Triazole-Resistant Infection and Utility of Airway Administration. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(8), 4146-4153. doi:10.1128/AAC.00141-12

    DOI: 10.1128/AAC.00141-12

    Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints (Journal article)

    Jeans, A. R., Howard, S. J., Al-Nakeeb, Z., Goodwin, J., Gregson, L., Majithiya, J. B., . . . Hope, W. W. (2012). Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints. JOURNAL OF INFECTIOUS DISEASES, 206(3), 442-452. doi:10.1093/infdis/jis372

    DOI: 10.1093/infdis/jis372

    Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection (Journal article)

    Livermore, J. L., Felton, T. W., Abbott, J., Sharp, A., Goodwin, J., Gregson, L., . . . Hope, W. W. (2013). Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(1), 281-288. doi:10.1128/AAC.01387-12

    DOI: 10.1128/AAC.01387-12

    Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection. (Journal article)

    Livermore, J. L., Felton, T. W., Abbott, J., Sharp, A., Goodwin, J., Gregson, L., . . . Hope, W. W. (2012). Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection.. Antimicrob Agents Chemother..

    Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens (Journal article)

    Hope, W. W., Goodwin, J., Felton, T. W., Ellis, M., & Stevens, D. A. (2012). Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(10), 5303-5308. doi:10.1128/AAC.00933-12

    DOI: 10.1128/AAC.00933-12

    Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections (Journal article)

    Felton, T. W., Hope, W. W., Lomaestro, B. M., Butterfield, J. M., Kwa, A. L., Drusano, G. L., & Lodise, T. P. (2012). Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(8), 4087-4094. doi:10.1128/AAC.00521-12

    DOI: 10.1128/AAC.00521-12

    Population Pharmacokinetics of Voriconazole in Adults (Journal article)

    Hope, W. W. (2012). Population Pharmacokinetics of Voriconazole in Adults. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(1), 526-531. doi:10.1128/AAC.00702-11

    DOI: 10.1128/AAC.00702-11

    Posaconazole: The Case for Therapeutic Drug Monitoring (Journal article)

    Howard, S. J., Felton, T. W., Gomez-Lopez, A., & Hope, W. W. (2012). Posaconazole: The Case for Therapeutic Drug Monitoring. THERAPEUTIC DRUG MONITORING, 34(1), 72-76. doi:10.1097/FTD.0b013e31823cdeac

    DOI: 10.1097/FTD.0b013e31823cdeac

    2011

    Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients (vol 55, pg 4782, 2011) (Journal article)

    Troke, P. F., Hockey, H. P., & Hope, W. W. (2011). Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients (vol 55, pg 4782, 2011). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(11), 5415. doi:10.1128/AAC.05771-11

    DOI: 10.1128/AAC.05771-11

    The management of Candida infections in preterm neonates and the role of micafungin (Journal article)

    Manzoni, P., Benjamin, D. K., Hope, W., Rizzollo, S., Del Sordo, P., Stronati, M., . . . Farina, D. (2011). The management of Candida infections in preterm neonates and the role of micafungin. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 24, 25-28. doi:10.3109/14767058.2011.604929

    DOI: 10.3109/14767058.2011.604929

    Robotic suturing on the FLS model possesses construct validity, is less physically demanding, and is favored by more surgeons compared with laparoscopy. (Journal article)

    Stefanidis, D., Hope, W. W., & Scott, D. J. (2011). Robotic suturing on the FLS model possesses construct validity, is less physically demanding, and is favored by more surgeons compared with laparoscopy.. Surgical endoscopy, 25(7), 2141-2146. doi:10.1007/s00464-010-1512-1

    DOI: 10.1007/s00464-010-1512-1

    Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis? (Journal article)

    Rodriguez-Tudela, J. L., Hope, W., Cuenca-Estrella, M., Donnelly, J. P., Lass-Flörl, C., & Arendrup, M. C. (2011). Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. Current Fungal Infection Reports, 5(3), 128-134. doi:10.1007/s12281-011-0058-6

    DOI: 10.1007/s12281-011-0058-6

    EUCAST Technical note on Amphotericin B (Journal article)

    Lass-Floerl, C., Arendrup, M. C., Rodriguez-Tudela, J. -L., Cuenca-Estrella, M., Donnelly, P., Hope, W., & Suscep, E. C. A. (2011). EUCAST Technical note on Amphotericin B. CLINICAL MICROBIOLOGY AND INFECTION, 17(12), E27-E29. doi:10.1111/j.1469-0691.2011.03644.x

    DOI: 10.1111/j.1469-0691.2011.03644.x

    EUCAST technical note on anidulafungin (Journal article)

    Arendrup, M. C., Rodriguez-Tudela, J. -L., Lass-Floerl, C., Cuenca-Estrella, M., Donnelly, J. P., Hope, W., & Suscep, E. C. A. (2011). EUCAST technical note on anidulafungin. CLINICAL MICROBIOLOGY AND INFECTION, 17(11), E18-E20. doi:10.1111/j.1469-0691.2011.03647.x

    DOI: 10.1111/j.1469-0691.2011.03647.x

    EUCAST technical note on posaconazole (Journal article)

    Arendrup, M. C., Cuenca-Estrella, M., Donnelly, J. P., Hope, W., Lass-Floerl, C., Rodriguez-Tudela, J. -L., & Suscep, E. C. A. (2011). EUCAST technical note on posaconazole. CLINICAL MICROBIOLOGY AND INFECTION, 17(11), E16-E17. doi:10.1111/j.1469-0691.2011.03646.x

    DOI: 10.1111/j.1469-0691.2011.03646.x

    Fluconazole Loading Dose Pharmacokinetics and Safety in Infants (Journal article)

    Piper, L., Smith, P. B., Hornik, C. P., Cheifetz, I. M., Barrett, J. S., Moorthy, G., . . . Jr, B. D. K. (2011). Fluconazole Loading Dose Pharmacokinetics and Safety in Infants. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 30(5), 375-378. doi:10.1097/INF.0b013e318202cbb3

    DOI: 10.1097/INF.0b013e318202cbb3

    Innate immunity in human newborn infants: prematurity means more than immaturity. (Journal article)

    Strunk, T., Currie, A., Richmond, P., Simmer, K., & Burgner, D. (2011). Innate immunity in human newborn infants: prematurity means more than immaturity.. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 24(1), 25-31. doi:10.3109/14767058.2010.482605

    DOI: 10.3109/14767058.2010.482605

    Optimizing management of invasive mould diseases (Journal article)

    Agrawal, S., Hope, W., Sinko, J., & Kibbler, C. (2011). Optimizing management of invasive mould diseases. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66, i45-i53. doi:10.1093/jac/dkq441

    DOI: 10.1093/jac/dkq441

    Pharmacodynamics of Echinocandins against Candida glabrata: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts (Journal article)

    Howard, S. J., Livermore, J., Sharp, A., Goodwin, J., Gregson, L., Alastruey-Izquierdo, A., . . . Hope, W. W. (2011). Pharmacodynamics of Echinocandins against Candida glabrata: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(10), 4880-4887. doi:10.1128/AAC.00621-11

    DOI: 10.1128/AAC.00621-11

    Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy (Journal article)

    Howard, S. J., Lestner, J. M., Sharp, A., Gregson, L., Goodwin, J., Slater, J., . . . Hope, W. W. (2011). Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy. JOURNAL OF INFECTIOUS DISEASES, 203(9), 1324-1332. doi:10.1093/infdis/jir023

    DOI: 10.1093/infdis/jir023

    Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants and Neonates (Journal article)

    Cohen-Wolkowiez, M., Jr, B. D. K., Piper, L., Cheifetz, I. M., Moran, C., Liu, P., . . . Smith, P. B. (2011). Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants and Neonates. CLINICAL PHARMACOLOGY & THERAPEUTICS, 89(5), 702-707. doi:10.1038/clpt.2011.26

    DOI: 10.1038/clpt.2011.26

    2010

    Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis (Journal article)

    Felton, T. W., Baxter, C., Moore, C. B., Roberts, S. A., Hope, W. W., & Denning, D. W. (2010). Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis. CLINICAL INFECTIOUS DISEASES, 51(12), 1383-1391. doi:10.1086/657306

    DOI: 10.1086/657306

    Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis (Journal article)

    Lestner, J. M., Howard, S. J., Goodwin, J., Gregson, L., Majithiya, J., Walsh, T. J., . . . Hope, W. W. (2010). Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(8), 3432-3441. doi:10.1128/AAC.01586-09

    DOI: 10.1128/AAC.01586-09

    Population Pharmacokinetics of Micafungin in Neonates and Young Infants (Journal article)

    Hope, W. W., Smith, P. B., Arrieta, A., Buell, D. N., Roy, M., Kaibara, A., . . . Jr, B. D. K. (2010). Population Pharmacokinetics of Micafungin in Neonates and Young Infants. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(6), 2633-2637. doi:10.1128/AAC.01679-09

    DOI: 10.1128/AAC.01679-09

    Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants (Journal article)

    Jr, B. D. K., Smith, P. B., Arrieta, A., Castro, L., Sanchez, P. J., Kaufman, D., . . . Walsh, T. J. (2010). Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants. CLINICAL PHARMACOLOGY & THERAPEUTICS, 87(1), 93-99. doi:10.1038/clpt.2009.200

    DOI: 10.1038/clpt.2009.200

    The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1 -> 3)-beta-D-Glucan, and Consequences of Delayed Antifungal Therapy (Journal article)

    Hope, W. W., Petraitis, V., Petraitiene, R., Aghamolla, T., Bacher, J., & Walsh, T. J. (2010). The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1 -> 3)-beta-D-Glucan, and Consequences of Delayed Antifungal Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(11), 4879-4886. doi:10.1128/AAC.00673-10

    DOI: 10.1128/AAC.00673-10

    Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? (Journal article)

    Roberts, J. A., Hope, W. W., & Lipman, J. (2010). Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential?. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 35(5), 419-420. doi:10.1016/j.ijantimicag.2010.01.022

    DOI: 10.1016/j.ijantimicag.2010.01.022

    Therapy for fungal diseases: opportunities and priorities (Journal article)

    Denning, D. W., & Hope, W. W. (2010). Therapy for fungal diseases: opportunities and priorities. TRENDS IN MICROBIOLOGY, 18(5), 195-204. doi:10.1016/j.tim.2010.02.004

    DOI: 10.1016/j.tim.2010.02.004

    2009

    Rational Testing Assessing candiduria in a critically ill patient (Journal article)

    Hope, W. W. (2009). Rational Testing Assessing candiduria in a critically ill patient. BRITISH MEDICAL JOURNAL, 338. doi:10.1136/bmj.b2289

    DOI: 10.1136/bmj.b2289

    Antifungal Therapeutic Drug Monitoring for Invasive Aspergillosis (Chapter)

    Howard, S. J., & Hope, W. W. (2009). Antifungal Therapeutic Drug Monitoring for Invasive Aspergillosis. In Aspergillosis: From Diagnosis to Prevention (pp. 217-228). Springer Netherlands. doi:10.1007/978-90-481-2408-4_14

    DOI: 10.1007/978-90-481-2408-4_14

    Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside (Journal article)

    Hope, W. W., & Drusano, G. L. (2009). Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. CLINICAL MICROBIOLOGY AND INFECTION, 15(7), 602-612. doi:10.1111/j.1469-0691.2009.02913.x

    DOI: 10.1111/j.1469-0691.2009.02913.x

    Aspergillus (Chapter)

    Malcolm, D., Richardson, K. B., & Hope, W. (2009). Aspergillus. In Clinical Mycology (pp. 271-296). Elsevier. doi:10.1016/b978-1-4160-5680-5.00011-6

    DOI: 10.1016/b978-1-4160-5680-5.00011-6

    Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose-Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis (Journal article)

    Petraitis, V., Petraitiene, R., Hope, W. W., Meletiadis, J., Mickiene, D., Hughes, J. E., . . . Walsh, T. J. (2009). Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose-Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(6), 2382-2391. doi:10.1128/AAC.00329-09

    DOI: 10.1128/AAC.00329-09

    Echinocandins (Chapter)

    Perlin, D. S., & Hope, W. W. (2009). Echinocandins. In Aspergillosis: From Diagnosis to Prevention (pp. 263-279). Springer Netherlands. doi:10.1007/978-90-481-2408-4_16

    DOI: 10.1007/978-90-481-2408-4_16

    Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis (Journal article)

    Hope, W. W. (2009). Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis. MEDICAL MYCOLOGY, 47, S291-S298. doi:10.1080/13693780802510232

    DOI: 10.1080/13693780802510232

    Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect (Journal article)

    Warn, P. A., Sharp, A., Parmar, A., Majithiya, J., Denning, D. W., & Hope, W. W. (2009). Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(8), 3453-3461. doi:10.1128/AAC.01601-08

    DOI: 10.1128/AAC.01601-08

    Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates (Journal article)

    Smith, P. B., Walsh, T. J., Hope, W., Arrieta, A., Takada, A., Kovanda, L. L., . . . Jr, B. D. K. (2009). Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 28(5), 412-415. doi:10.1097/INF.0b013e3181910e2d

    DOI: 10.1097/INF.0b013e3181910e2d

    Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring (Journal article)

    Lestner, J. M., Roberts, S. A., Moore, C. B., Howard, S. J., Denning, D. W., & Hope, W. W. (2009). Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring. CLINICAL INFECTIOUS DISEASES, 49(6), 928-930. doi:10.1086/605499

    DOI: 10.1086/605499

    2008

    Cerebrospinal Fluid and Plasma (1 -> 3)-beta-D-Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental Hematogenous Candida Meningoencephalitis (Journal article)

    Petraitiene, R., Petraitis, V., Hope, W. W., Mickiene, D., Kelaher, A. M., Murray, H. A., . . . Walsh, T. J. (2008). Cerebrospinal Fluid and Plasma (1 -> 3)-beta-D-Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental Hematogenous Candida Meningoencephalitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 4121-4129. doi:10.1128/AAC.00674-08

    DOI: 10.1128/AAC.00674-08

    Experimental Design Considerations in Pharmacokinetic Studies (Chapter)

    Hope, W. W., Petraitis, V., & Walsh, T. J. (n.d.). Experimental Design Considerations in Pharmacokinetic Studies. In Preclinical Development Handbook (pp. 1059-1068). John Wiley & Sons, Inc.. doi:10.1002/9780470249031.ch31

    DOI: 10.1002/9780470249031.ch31

    Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group (Journal article)

    De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., . . . Bennett, J. E. (2008). Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. CLINICAL INFECTIOUS DISEASES, 46(12), 1813-1821. doi:10.1086/588660

    DOI: 10.1086/588660

    The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: Implications for echinocandin therapy in neonates (Journal article)

    Hope, W. W., Mickiene, D., Petraitis, V., Petraitiene, R., Kelaher, A. M., Hughes, J. E., . . . Walsh, T. J. (2008). The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: Implications for echinocandin therapy in neonates. JOURNAL OF INFECTIOUS DISEASES, 197(1), 163-171. doi:10.1086/524063

    DOI: 10.1086/524063

    Therapeutic drug monitoring for triazoles (Journal article)

    Hope, W. W., Billaud, E. M., Lestner, J., & Denning, D. W. (2008). Therapeutic drug monitoring for triazoles. CURRENT OPINION IN INFECTIOUS DISEASES, 21(6), 580-586. doi:10.1097/QCO.0b013e3283184611

    DOI: 10.1097/QCO.0b013e3283184611

    2007

    Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: Implications for antifungal therapy (Journal article)

    Hope, W. W., Kruhlak, M. J., Lyman, C. A., Petraitiene, R., Petraitis, V., Francesconi, A., . . . Walsh, T. J. (2007). Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: Implications for antifungal therapy. JOURNAL OF INFECTIOUS DISEASES, 195(3), 455-466. doi:10.1086/510535

    DOI: 10.1086/510535

    Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis (Journal article)

    Hope, W. W., Drusano, G. L., Moore, C. B., Sharp, A., Louie, A., Walsh, T. J., . . . Warn, P. A. (2007). Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(1), 285-295. doi:10.1128/AAC.00601-06

    DOI: 10.1128/AAC.00601-06

    Galactomannan antigen detection in the diagnosis of invasive aspergillosis (Journal article)

    Verdaguer, V., Walsh, T. J., Hope, W., & Cortez, K. J. (2007). Galactomannan antigen detection in the diagnosis of invasive aspergillosis. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 7(1), 21-32. doi:10.1586/14737159.7.1.21

    DOI: 10.1586/14737159.7.1.21

    Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing (Journal article)

    Hope, W. W., Warn, P. A., Sharp, A., Reed, P., Keevil, B., Louie, A., . . . Drusano, G. L. (2007). Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(10), 3760-3762. doi:10.1128/AAC.00488-07

    DOI: 10.1128/AAC.00488-07

    Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing (Journal article)

    Hope, W. W., Seibel, N. L., Schwartz, C. L., Arrieta, A., Flynn, P., Shad, A., . . . Walsh, T. J. (2007). Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(10), 3714-3719. doi:10.1128/AAC.00398-07

    DOI: 10.1128/AAC.00398-07

    The pharmacology and clinical use of caspofungin (Journal article)

    Hope, W. W., Shoham, S., & Walsh, T. J. (2007). The pharmacology and clinical use of caspofungin. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 3(2), 263-274. doi:10.1517/17425255.3.2.263

    DOI: 10.1517/17425255.3.2.263

    2006

    Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis (Journal article)

    Francesconi, A., Kasai, M., Petraitiene, R., Petraitis, V., Kelaher, A. M., Schaufele, R., . . . Walsh, T. J. (2006). Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. JOURNAL OF CLINICAL MICROBIOLOGY, 44(7), 2475-2480. doi:10.1128/JCM.02693-05

    DOI: 10.1128/JCM.02693-05

    Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt (Journal article)

    Anaissie, E. J., Segal, B. H., Graybill, J. R., Arndt, C., Perfect, J. R., Kleinberg, M., . . . Zaoutis, T. (2006). Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt. CLINICAL INFECTIOUS DISEASES, 43(8), 1031-1039. doi:10.1086/509116

    DOI: 10.1086/509116

    Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect (Journal article)

    Hope, W. W., Warn, P. A., Sharp, A., Howard, S., Kasai, M., Louie, A., . . . Denning, D. W. (2006). Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 50(11), 3680-3688. doi:10.1128/AAC.00369-06

    DOI: 10.1128/AAC.00369-06

    2005

    Laboratory diagnosis of invasive aspergillosis (Journal article)

    Hope, W. W., Walsh, T. J., & Denning, D. W. (2005). Laboratory diagnosis of invasive aspergillosis. LANCET INFECTIOUS DISEASES, 5(10), 609-622. doi:10.1016/S1473-3099(05)70238-3

    DOI: 10.1016/S1473-3099(05)70238-3

    Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis (Journal article)

    Hope, W. W., Warn, P. A., Sharp, A., Reed, P., Keevil, B., Louie, A., . . . Drusano, G. L. (2005). Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. JOURNAL OF INFECTIOUS DISEASES, 192(4), 673-680. doi:10.1086/432069

    DOI: 10.1086/432069

    The invasive and saprophytic syndromes due to Aspergillus spp. (Journal article)

    Hope, W. W., Walsh, T. J., & Denning, D. W. (2005). The invasive and saprophytic syndromes due to Aspergillus spp.. MEDICAL MYCOLOGY, 43, S207-S238. doi:10.1080/13693780400025179

    DOI: 10.1080/13693780400025179

    2004

    A PCR method for the identification of methicillin-resistant Staphylococcus aureus (MRSA) from screening swabs (Journal article)

    Hope, W. W., Morton, A. P., Looke, D. F. M., Schooneveldt, J. M., & Nimmo, G. R. (2004). A PCR method for the identification of methicillin-resistant Staphylococcus aureus (MRSA) from screening swabs. PATHOLOGY, 36(3), 265-268. doi:10.1080/00313020410001692530

    DOI: 10.1080/00313020410001692530

    Invasive aspergillosis: current and future challenges in diagnosis and therapy (Journal article)

    Hope, W. W., & Denning, D. W. (2004). Invasive aspergillosis: current and future challenges in diagnosis and therapy. CLINICAL MICROBIOLOGY AND INFECTION, 10(1), 2-4. doi:10.1111/j.1469-0691.2004.00809.x

    DOI: 10.1111/j.1469-0691.2004.00809.x

    Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens (Journal article)

    Hope, W. W., Padwell, A., Guiver, M., & Denning, D. W. (2004). Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. JOURNAL OF INFECTION, 49(2), 136-140. doi:10.1016/j.jinf.2004.02.008

    DOI: 10.1016/j.jinf.2004.02.008

    Molecular mechanisms of primary resistance to flucytosine in Candida albicans (Journal article)

    Hope, W. W., Tabernero, L., Denning, D. W., & Anderson, M. J. (2004). Molecular mechanisms of primary resistance to flucytosine in Candida albicans. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 48(11), 4377-4386. doi:10.1128/AAC.48.11.4377-4386.2004

    DOI: 10.1128/AAC.48.11.4377-4386.2004

    Optimising antifungal therapy for individual patients (Journal article)

    Hope, W. W., & Denning, D. W. (2004). Optimising antifungal therapy for individual patients. INTERNAL MEDICINE JOURNAL, 34(4), 147-149. doi:10.1111/j.1444-0903.2004.00569.x

    DOI: 10.1111/j.1444-0903.2004.00569.x

    2003

    Sequential infection with Nocardia farcinica and Cryptococcus neoformans var. gattii in an immunocompetent host (Journal article)

    Hope, W., & Looke, D. (2003). Sequential infection with Nocardia farcinica and Cryptococcus neoformans var. gattii in an immunocompetent host. JOURNAL OF INFECTION, 47(3), 256-259. doi:10.1016/S0163-4453(03)00083-5

    DOI: 10.1016/S0163-4453(03)00083-5

    2002

    A case of bacteremic pyelonephritis due to Pasteurella multocida subsp. multocida (Journal article)

    Hope, W. W., Flohr, G., & Nimmo, G. R. (2002). A case of bacteremic pyelonephritis due to Pasteurella multocida subsp. multocida. Clinical Microbiology Newsletter, 24(18), 140-141. doi:10.1016/s0196-4399(02)80036-8

    DOI: 10.1016/s0196-4399(02)80036-8

    Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use (Journal article)

    Hope, W., Morton, A., & Eisen, D. P. (2002). Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. JOURNAL OF HOSPITAL INFECTION, 50(1), 56-65. doi:10.1053/jhin.2001.1131

    DOI: 10.1053/jhin.2001.1131

    Urine D-arabinitol/L-arabinitol ratio in diagnosing Candida infection in patients with haematological malignancy and HIV infection (Journal article)

    Eisen, D. P., Bartley, P. B., Hope, W., Sigmundsdottir, G., Pehrson, C., Larsson, L., & Christensson, B. (2002). Urine D-arabinitol/L-arabinitol ratio in diagnosing Candida infection in patients with haematological malignancy and HIV infection. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 42(1), 39-42. doi:10.1016/S0732-8893(01)00310-8

    DOI: 10.1016/S0732-8893(01)00310-8